Sera Prognostics Inc
Change company Symbol lookup
Select an option...
SERA Sera Prognostics Inc
SPCE Virgin Galactic Holdings Inc
BBLG Bone Biologics Corp
RPT RPT Realty
CLM Cornerstone Strategic Value Fund
RCI Rogers Communications Inc
ADRA Adara Acquisition Corp
EVTC Evertec Inc
OPEN Opendoor Technologies Inc
XAIR Beyond Air Inc
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Sera Prognostics, Inc. is a women’s health diagnostic company that is focused on utilizing its proteomics and bioinformatics platform to discover, develop and commercialize clinically impactful biomarker tests, with an initial focus on improving pregnancy outcomes. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. The Company's commercial product, the PreTRM test, is a blood-based biomarker test to accurately predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 19 or 20 of gestation. Its biomarker pregnancy pipeline includes preeclampsia, molecular time-to-birth, gestational diabetes mellitus (GDM), fetal growth restriction, stillbirth and postpartum depression.

Postmarket

Last Trade
Delayed
$2.58
-0.13 (-4.80%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$2.71
Day's Change
0.31 (12.92%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
2.80
Day's Low
2.40
Volume
(Heavy Day)
Volume:
66,985

10-day average volume:
22,492
66,985

Company Profile

Sera Prognostics, Inc. is a women’s health diagnostic company that is focused on utilizing its proteomics and bioinformatics platform to discover, develop and commercialize clinically impactful biomarker tests, with an initial focus on improving pregnancy outcomes. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. The Company's commercial product, the PreTRM test, is a blood-based biomarker test to accurately predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 19 or 20 of gestation. Its biomarker pregnancy pipeline includes preeclampsia, molecular time-to-birth, gestational diabetes mellitus (GDM), fetal growth restriction, stillbirth and postpartum depression.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
659.17x
Price/Book (MRQ)
0.55x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

July 2022
Current Month
116.5K
Previous Month
243.5K
Percent of Float
0.46%
Days to Cover
1.0945 Days

Share Information

SERA is in a share class of common stock
Float
25.1M
Shares Outstanding
30.9M
Institutions Holding Shares
69
56.10%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Gregory C. CritchfieldChmn.
  • Jay M. MoyesCFO
  • Robert Gardner HarrisonCIO
  • Jay BonifaceCSO
  • Benjamin G. JacksonCounsel

Address

Insider Trading

During the most recent quarter, 8K shares were bought, and 60K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.